The Latest Breaking News from Moderna

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK · Apr 21, 2022

If You Invested $1,000 In Moderna Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga · Apr 20, 2022

Parents of kids under 5 still waiting for COVID shots

The demise of the federal transportation mask mandate was particularly jarring for many parents of children under five anxiously waiting for word on when COVID shots will become available to their kids.

Axios · Apr 20, 2022

J&J suspends COVID-19 vaccine sales forecast

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year

The Independent UK · Apr 19, 2022

Moderna Says Dual Variant Booster with Beta More Effective vs. Omicron than Current Shot

Moderna Inc on Tuesday said a COVID-19 booster designed to target the Beta variant as well as the original coronavirus generated a better immune response against a number of virus variants including Omicron. Moderna said the results were a good sign for the company's plans for future shots targeting two…

Asharq Al-Awsat · Apr 19, 2022

Scientists developing 'blockbuster' heart attack cure using Covid vaccine tech

Researchers from King's College London are working on regenerating damaged hearts in the hope of developing a cure for heart attacks - with human trials set to begin within two years.

Daily Record · Apr 18, 2022

What Are Whales Doing With Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Apr 14, 2022

Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19…

Benzinga · Apr 14, 2022

Moderna Covid vaccine approved in UK children's jabs for ages six to 11

The vaccine's rollout still depends on the verdict of the Joint Committee on Vaccination Immunisation.

Daily Record · Apr 14, 2022

Moderna vaccine given go-ahead for use on six to 11-year-olds in UK

A decision on whether it will be offered still has to be made

Wales Online · Apr 14, 2022